Association Between Metformin Therapy and Mortality After Breast Cancer
A population-based study
- Iliana C. Lega, MD1⇑,
- Peter C. Austin, PHD2,3,
- Andrea Gruneir, PHD1,2,3,
- Pamela J. Goodwin, MD, MSC2,4,
- Paula A. Rochon, MD, MPH1,2,3 and
- Lorraine L. Lipscombe, MD, MSC1,2,3
- 1Women’s College Research Institute, Women’s College Hospital, Toronto, Ontario, Canada
- 2Institute of Health Policy Management and Evaluation, University of Toronto, Toronto, Ontario, Canada
- 3The Institute for Evaluative and Clinical Sciences, Toronto, Ontario, Canada
- 4Samuel Lunenfeld Research Institute, Mount Sinai Hospital, Toronto, Ontario, Canada.
- Corresponding author: Iliana C. Lega, .
OBJECTIVE Metformin has been associated with a reduction in breast cancer risk and may improve survival after cancer through direct and indirect tumor-suppressing mechanisms. The purpose of this study was to evaluate the effect of metformin therapy on survival in women with breast cancer using methods that accounted for the duration of treatment with glucose-lowering therapies.
RESEARCH DESIGN AND METHODS This population-based study, using Ontario health care databases, recruited women aged 66 years or older diagnosed with diabetes and breast cancer between 1 April 1997 and 31 March 2008. Using Cox regression analyses, we explored the association between cumulative duration of past metformin use and all-cause and breast cancer–specific mortality. We modeled cumulative duration of past metformin use as a time-varying exposure.
RESULTS Of 2,361 breast cancer patients identified, mean (± SD) age at cancer diagnosis was 77.4 ± 6.3 years, and mean follow-up was 4.5 ± 3.0 years. There were 1,101 deaths(46.6%), among which 386 (16.3%) were breast cancer–specific deaths. No significant association was found between cumulative duration of past metformin use and all-cause mortality (adjusted hazard ratio 0.97 [95% CI 0.92–1.02]) or breast cancer–specific mortality (0.91 [0.81–1.03]) per additional year of cumulative use.
CONCLUSIONS Our findings failed to show an association between improved survival and increased cumulative metformin duration in older breast cancer patients who had recent-onset diabetes. Further research is needed to clarify this association, accounting for effects of cancer stage and BMI in younger populations or those with differing stages of diabetes as well as in nondiabetic populations.
- Received December 5, 2012.
- Accepted April 3, 2013.
- © 2013 by the American Diabetes Association.
Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. See http://creativecommons.org/licenses/by-nc-nd/3.0/ for details.